We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck's (MRK) Keytruda Combo Meets Goal in Kidney Cancer Study
Read MoreHide Full Article
Merck (MRK - Free Report) and partner Eisai announced positive top-line data from a pivotal phase III study evaluating a combination of Merck’s anti-PD-1 therapy, Keytruda,plus Eisai’s multiple receptor tyrosine kinase inhibitor Lenvima for the first-line treatment of patients with advanced renal cell carcinoma (RCC),a kind of kidney cancer.
Shares of the company have decreased 8.7% year to date against the industry’s 3.4% growth.
The results from the KEYNOTE-581/CLEAR (Study 307) study showedthat Keytruda plus Lenvima demonstrated statistically significant improvement in progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) versus Pfizer’s (PFE - Free Report) RCC drug, Sutent (sunitinib), in the intention-to-treat (ITT) study population.
Additionally, Lenvimaplus everolimus met the study’s primary endpoint of PFS and a key secondary endpoint of ORR, demonstrating a statistically significant and clinically meaningful improvement in both metrics versus the sunitinib combination in the ITT study population.
Merck and Eisai plan to submit marketing authorization applications based on these results and thus, the companies will discuss these data with regulatory authorities worldwide.
The companies are also continuing to study the Keytruda plus Lenvima combination through the LEAP (LEnvatinib and Pembrolizumab) clinical program across 19 studies in 13 different tumor types.
Keytruda is already approved for use in 30 indications across several different tumor types in the United States.
BioLineRx’s loss per share estimates have narrowed from $1.95 to $1.67 for 2020 and from $1.44 to $1.36 for 2021 in the past 60 days. Shares of the company have increased 7.1% year to date.
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Image: Bigstock
Merck's (MRK) Keytruda Combo Meets Goal in Kidney Cancer Study
Merck (MRK - Free Report) and partner Eisai announced positive top-line data from a pivotal phase III study evaluating a combination of Merck’s anti-PD-1 therapy, Keytruda,plus Eisai’s multiple receptor tyrosine kinase inhibitor Lenvima for the first-line treatment of patients with advanced renal cell carcinoma (RCC),a kind of kidney cancer.
Shares of the company have decreased 8.7% year to date against the industry’s 3.4% growth.
The results from the KEYNOTE-581/CLEAR (Study 307) study showedthat Keytruda plus Lenvima demonstrated statistically significant improvement in progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) versus Pfizer’s (PFE - Free Report) RCC drug, Sutent (sunitinib), in the intention-to-treat (ITT) study population.
Additionally, Lenvimaplus everolimus met the study’s primary endpoint of PFS and a key secondary endpoint of ORR, demonstrating a statistically significant and clinically meaningful improvement in both metrics versus the sunitinib combination in the ITT study population.
Merck and Eisai plan to submit marketing authorization applications based on these results and thus, the companies will discuss these data with regulatory authorities worldwide.
The companies are also continuing to study the Keytruda plus Lenvima combination through the LEAP (LEnvatinib and Pembrolizumab) clinical program across 19 studies in 13 different tumor types.
Keytruda is already approved for use in 30 indications across several different tumor types in the United States.
Zacks Rank and A Stocks to Consider
Merck currently has a Zacks Rank #3 (Hold).
A better-ranked stock in the biotech sector is BioLineRx Ltd, , carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
BioLineRx’s loss per share estimates have narrowed from $1.95 to $1.67 for 2020 and from $1.44 to $1.36 for 2021 in the past 60 days. Shares of the company have increased 7.1% year to date.
Merck Co., Inc. Price
Merck Co., Inc. price | Merck Co., Inc. Quote
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Click here for the 6 trades >>